BNP Paribas Financial Markets Buys 32,072 Shares of Altimmune, Inc. (NASDAQ:ALT)

BNP Paribas Financial Markets increased its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 318.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,140 shares of the company’s stock after purchasing an additional 32,072 shares during the quarter. BNP Paribas Financial Markets’ holdings in Altimmune were worth $259,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after buying an additional 335,444 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Altimmune during the second quarter valued at approximately $860,000. Los Angeles Capital Management LLC bought a new stake in Altimmune during the second quarter worth $689,000. Exchange Traded Concepts LLC boosted its holdings in shares of Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after purchasing an additional 92,498 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Altimmune by 28.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock valued at $1,621,000 after purchasing an additional 54,154 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on ALT shares. UBS Group began coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Stock Down 0.3 %

Shares of ALT stock opened at $9.00 on Tuesday. The firm has a market capitalization of $640.13 million, a P/E ratio of -5.81 and a beta of 0.15. Altimmune, Inc. has a twelve month low of $5.28 and a twelve month high of $14.84. The stock’s fifty day simple moving average is $7.77 and its 200 day simple moving average is $7.08.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the prior year, the company earned ($0.39) EPS. As a group, equities research analysts expect that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.